• The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer.
• The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development.
• VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics.
• Recent regulatory feedback from Germany’s Paul-Ehrlich-Institute has provided additional clarity for development of the company’s lead BiTAC(R)-TCE program.
• Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics researcher Christoph Erkel, Ph.D., as Chief Scientific Officer, reinforcing the company’s focus on advancing its proprietary BiTAC(R) technology platform as it prepares its lead oncology programs for clinical development. The announcement comes at a time when the biotechnology company is moving several elements of its research pipeline forward while expanding its scientific and regulatory capabilities.

According to the company, Dr. Erkel previously served as Vice President of Research & Development, where he helped oversee development of VERAXA’s antibody therapeutics portfolio. In his new role, he will lead scientific strategy across the company’s BiTAC(R) platforms and broader oncology pipeline while directing efforts to accelerate product candidates toward human clinical trials (https://ibn.fm/fc9tP).

Dr. Erkel brings approximately two decades of experience in antibody engineering, immuno-oncology research and preclinical drug development. Before joining VERAXA, he led therapeutic research programs at MorphoSys AG, where he worked on conditionally active T-cell engagers and other antibody-based therapies prior to the company’s acquisition by Novartis. His career has also included leadership positions in antibody engineering and molecular biology, spanning both scientific discovery and candidate development.

The appointment reflects a broader phase of development for VERAXA as it seeks to translate laboratory research into clinical-stage oncology programs. The company’s strategy centers on antibody therapeutics designed to improve the precision of cancer treatment. While traditional immunotherapies have transformed oncology, researchers continue searching for approaches that preserve anti-tumor activity while minimizing damage to healthy tissue.

VERAXA’s lead development program is built around its proprietary BiTAC(R)-TCE technology, a conditionally active bispecific T-cell engager designed to recognize two tumor-associated markers before activating an immune response. Management believes this dual-targeting approach may improve selectivity by directing immune cells primarily toward cancer cells expressing both markers, potentially reducing activity against healthy cells displaying only one target.

Earlier this month, the company also announced encouraging regulatory progress after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute, which supported the biological rationale and proposed non-clinical development strategy for its lead BiTAC(R)-TCE candidate. The feedback provided additional clarity as the program advances toward future regulatory submissions.

Initial preclinical findings presented at the American Association for Cancer Research (“AACR”) Annual Meeting in April demonstrated that the company’s lead candidate selectively attacked cancer cells expressing both target molecules while sparing cells expressing only one marker. According to VERAXA, those studies also indicated efficacy comparable to conventional T-cell engagers while suggesting the potential for an improved therapeutic index if confirmed in future development.

Questions Investors May Be Asking About BiTAC(R)

What makes BiTAC(R) different from conventional T-cell engagers?

Traditional T-cell engagers generally activate immune cells whenever a single target is detected, which can increase the risk of attacking healthy tissues that also express that marker. VERAXA’s BiTAC(R) technology is designed to require recognition of two tumor-associated targets before triggering immune-cell activation, an approach intended to increase selectivity and potentially improve safety. A conditionally active T-cell binding CD3 domain adds another layer of safety control to BiTAC-TCEs.

Why is there continued demand for new T-cell engager technologies?

Although T-cell engagers have become an important area of cancer drug development, many researchers continue working to reduce treatment-related toxicity while expanding their use against solid tumors. Technologies that improve targeting precision could broaden the range of patients who may benefit from these therapies if clinical results support the approach.

Where do antibody-drug conjugates (“ADCs”) fit into VERAXA’s strategy?

Beyond BiTAC(R), VERAXA is developing a broader pipeline that includes other bispecific antibody-drug conjugate formats. ADCs combine antibodies with potent therapeutic payloads that are delivered directly to cancer cells, while bispecific formats seek to further improve targeting by recognizing multiple biomarkers simultaneously. Together, these platforms provide multiple development opportunities across different cancer indications.

VERAXA’s broader strategy extends beyond a single product candidate. The company is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific antibody-drug conjugates and additional engineered antibody formats designed for solid tumors and other cancer types.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]

InvestorWire is powered by IBN